Over 90 California Auctions End Today - Bid Now
Over 70 Total Lots Up For Auction at One Location - CA 03/27

Philochem AG, Seibersdorf Labor GmbH and Isotopia announce supply, development, and manufacturing agreements

Press releases may be edited for formatting or style | December 15, 2022 Molecular Imaging
OTELFINGEN, Switzerland, SEIBERSDORF, Austria and PETAH TIKVA, Israel, Dec. 13, 2022 /PRNewswire/ -- Philochem, Seibersdorf Laboratories and Isotopia Molecular Imaging have today announced that they have signed agreements that will help advance the next generation of Radiopharmaceutical Therapies for cancer treatment.

Under these agreements, Isotopia will supply high quality 177 Lu-n.c.a to Seibersdorf Laboratories for the purpose of conducting development and manufacturing activities for Philochem's proprietary therapeutic candidate, OncoFAP-23.

OncoFAP-23 is a novel small molecule ligand developed for Targeted Radionuclide Therapy which selectively binds to Fibroblast Activation Protein (FAP), an antigen expressed in a variety of solid human malignancies, while being undetectable in most healthy tissues. Philochem's scientists demonstrated that 177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands.

Your Centrifuge Specialty Store

Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576

177Lu n.c.a is used in Targeted Radionuclide Therapy in the field of Precision Medicine in Oncology. By binding n.c.a. 177Lu isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of 177Lu. 177Lu n.c.a contains no Mercury (Hg) and no metastable 177Lu-m, therefore there is no need for cost intensive clinical waste management.

Seibersdorf's CEO, Martina Schwaiger stated: "The new agreement is a great opportunity for our team and we are pleased to be working with Philochem and Isotopia Molecular Imaging on this important sector of medical care."

Sammuele Cazzamalli, PhD, Head of Small Molecule Therapeutics at Philochem commented: " We are delighted to start working with Isotopia and Seibersdorf Laboratories on the manufacturing of our Targeted Radioligand Therapeutics. This collaboration is important to pursue Philochem's bench-to-bedside translational research, with competitive timelines, on our novel best-in-class 177Lu-OncoFAP-23."

"This three-way collaboration demonstrates the ability to provide the full support for clinical development" stated Keren Moshkoviz, Director of Business Development at Isotopia. "Isotopia's aim is to play a significant role in early developments that will benefit patients in the future. We try to build a platform that can drive new products into the clinic in a simple and agile way.

You Must Be Logged In To Post A Comment